SAB Biotherapeutics (SABS) Operating Expenses (2020 - 2026)

SAB Biotherapeutics (SABS) has 7 years of Operating Expenses data on file, last reported at $20.0 million in Q1 2026.

• Quarterly Operating Expenses rose 85.64% year-over-year to $20.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $58.2 million (up 36.35% YoY) and the FY2025 annual result came in at $49.0 million, up 10.67% from the prior year.
• Operating Expenses rose to $20.0 million in Q1 2026, from $15.8 million in the prior quarter.
• In the past five years, Operating Expenses ranged from a high of $20.0 million in Q1 2026 to a low of $6.6 million in Q2 2023.
• A 5-year average of $12.1 million and a median of $11.3 million in 2024 frame the typical range for Operating Expenses.
• The widest YoY moves for Operating Expenses: up 91.39% in 2023, down 56.87% in 2023.
• Tracing SABS's Operating Expenses over 5 years: stood at $10.0 million in 2022, then jumped by 91.39% to $19.2 million in 2023, then sank by 47.21% to $10.1 million in 2024, then jumped by 55.78% to $15.8 million in 2025, then advanced by 26.81% to $20.0 million in 2026.
• The last three Operating Expenses figures came in at $20.0 million (Q1 2026), $15.8 million (Q4 2025), and $12.7 million (Q3 2025), per Business Quant data.